topic

601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC
Tianshi Lu, Mark A Socinski, Martin Reck, Howard West, Federico Cappuzzo, Fabrice Barlesi, Robert M Jotte, Sören Müller, Habib Hamidi, Assaf Amitai, Hartmut Koeppen, David S Shames, Marcus Ballinger, Aditi Qamra, Minu K Srivastava, Barzin Nabet

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A684; DOI: 10.1136/jitc-2023-SITC2023.0601
602 A phase I trial of atezolizumab and varlilumab in combination with radiation in patients with metastatic non-small cell lung cancer (NSCLC)
Jyoti Malhotra, Yong Lin, Malini Patel, Michael J Yellin, Emmanuel Zachariah, Curtis Krier, Ankit Saxena, Salma K Jabbour

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A685; DOI: 10.1136/jitc-2023-SITC2023.0602
603 Phase II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): big ten cancer research consortium (BTCRC-LUN17–127) study
Jyoti Malhotra, Alberto Chiappori, Naomi Fujioka, Nasser H Hanna, Lawrence E Feldman, Malini Patel, Dirk Moore, Chunxia Chen, Salma K Jabbour

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A686; DOI: 10.1136/jitc-2023-SITC2023.0603
604 Clinical and molecular findings from a randomized phase II study of epigenetic priming with azacitidine and entinostat followed by nivolumab in previously treated metastatic non-small cell lung cancer
Kristen A Marrone, Blair V Landon, Michael J Topper, Hua-Ling Tsai, Archana Balan, Noushin Niknafs, Christopher Cherry, James White, Chen Hu, Joanne Riemer, Margaret Fitzpatrick, Patrick Forde, Christine Hann, Ronan Kelly, David Ettinger, Benjamin Levy, Jorge Nieva, James Herman, Victor Velculescu, Valsamo Anagnostou, Stephen Baylin, Julie Brahmer

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A687; DOI: 10.1136/jitc-2023-SITC2023.0604
605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
Guenter Schmidt, Jan Lesniak, Thomas Kunzke, Federico Pollastri, Markus Schick, Johannes Zimmermann, Ross Stewart

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A688-A689; DOI: 10.1136/jitc-2023-SITC2023.0605
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
Minu K Srivastava, Velimir Gayevskiy, Vy Ma, Ivette Estay, Miguel Lopez de Rodas, Barani Kumar Rajendran, Tien Hoang, Marcus Ballinger, Reena Amin, Roy S Herbst, Filippo de Marinis, Giuseppe Giaccone, Jacek Jassem, David R Spigel, Kurt Schalper, Hartmut Koeppen, David S Shames, Robert Johnston, Jennifer M Giltnane, Barzin Y Nabet

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A690; DOI: 10.1136/jitc-2023-SITC2023.0606
607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study
Jeffrey Ward, Ticiana A Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo Dols, Jaromír Roubec, Luboš Petruželka, Libor Havel, Sujith Kalmadi, Zoran Andric, Thierry Berghmans, David E Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey Langer

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A691; DOI: 10.1136/jitc-2023-SITC2023.0607
608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
Christopher T Chen, Erika Hamilton, Patricia LoRusso, Sylvie Rottey, Kyriakos P Papadopoulos, Shivaani Kummar, Nuria Kotecki, Fiona C Thistlethwaite, Yvan LeBruchec, Jerzy Dyczkowski, Josef Rüschoff, Sara Samari, Marie Toukam, Joseph Boni, Karin Havenith, Serafino Pantano, Igor Puzanov

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A692; DOI: 10.1136/jitc-2023-SITC2023.0608
609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
Dylan M Glatt, Sariah Kell, Maike Schmidt, Sophia R Majeed

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A693; DOI: 10.1136/jitc-2023-SITC2023.0609
610 ImmunoRad: a stratified phase II trial of image guided hypofractionated radiotherapy with concurrent nelfinavir & PD-1 inhibition in advanced melanoma, lung cancer & renal cell carcinoma
Peter H Goff, Kelsey K Baker, Sylvia M Lee, Scott S Tykodi, Shailender Bhatia, Jing Zeng, Mary Redman, Ramesh Rengan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A694; DOI: 10.1136/jitc-2023-SITC2023.0610

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages